Abstract
Isolated tricuspid valve replacement, which is not a common operation, is associated with poor shortand long-term results, and the postoperative morbidity and mortality rates are high. The main reason for these adverse effects is the acute manifestation of chronic right heart failure. To treat right heart failure, we used levosimendan for its inotropic and vasodilatatory effects, and it does not increase the calcium overload in myocardial cells. We report two cases of tricuspid valve replacement operations performed using levosimendan. Both patients receiving levosimendan tolerated the operations well, and their postoperative courses were uneventful.
Similar content being viewed by others
References
Scully HE, Armstrong CS. Tricuspid valve replacement: fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg 1995;109:1035–1041.
Jegaden O, Perinetti M, Barthelet M, Vedrinne C, Delahaye F, Montagna P, et al. Long-term results of porcine bioprostheses in the tricuspid position. Eur J Cardiothorac Surg 1992;6:256–260.
Iscan ZH, Vural KM, Bahar I, Mavioglu L, Saritas A. What to expect after tricuspid valve replacement? Long-term results. Eur J Cardiothorac Surg 2007;32:296–300.
Mangoni AA, DiSalvo TG, Vlahakes GJ, Polanczyk CA, Fifer MA. Outcome following isolated tricuspid valve replacement. Eur J Cardiothorac Surg 2001;19:68–73.
Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting—a pilot study. Br J Anaesth 2006;96:694–700.
Morais RJ. Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth 2006;20:82–84.
Westphal M, Morelli A, Van Aken H. Dear levosimendan, the right ventricle will thank you! Crit Care Med 2007;35:952–953.
Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556–569.
Filsoufi F, Anyanwu AC, Salzberg SP, Frankel T, Cohn LH, Adams DH. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg 2005;80:845–850.
Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249–259.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cicekcioglu, F., Parlar, A.I., Altinay, L. et al. Tricuspid valve replacement and levosimendan. Gen Thorac Cardiovasc Surg 56, 559–562 (2008). https://doi.org/10.1007/s11748-008-0298-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-008-0298-8